*僅供醫學專業人士閱讀參考
直擊2024 SABCS，見證治療革新
撰文 | lily
2024年12月10日-13日，第47屆聖安東尼奧乳腺癌研討會（SABCS）將在美國聖安東尼奧隆重舉行。作為乳腺癌研究領域中規模最大、最具盛名的科學聚會之一，SABCS大會集結了近一年來乳腺癌領域的最新研究成果、臨床實踐經驗、治療進展和技術創新等內容。
日前，大會公佈了摘要標題。醫學界特對LBA Oral Session、General Session、Rapid Fire Session的口頭報告研究進行整理，涉及圍手術期治療、症狀監測、基因檢測、風險評估等多項拓展分析研究，以供讀者參考。
圍手術期相關研究
LBA Oral Session
摘要號：LB1-01
Long-term effects of the omission of immediate surgery in operable breast cancer, or reduction of surgical extent: patient-level meta-analysis of the four randomised trials among 2,514 women.
可手術乳腺癌不立即手術或手術範圍縮小的長期影響：對2,514名女性的四項隨機試驗的患者水平薈萃分析。
講者：Robert Hills, University of Oxford, Oxford, United Kingdom
General Session
摘要號：GS1-08
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study.
降低風險手術與攜帶BRCA突變的年輕乳腺癌患者生存情況的關係：一項國際佇列研究的結果
講者：Matteo Lambertini, University of Genova, Genova, Italy
摘要號：GS2-02
Impact of Tamoxifen Only after Breast Conservation Surgery for "Good Risk" Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial
僅在“低風險”的乳腺導管原位癌患者接受保乳術後使用他莫昔芬治療的影響：來自NRG Oncology/RTOG 9804和ECOG-ACRIN E5194試驗的結果
講者：Jean Wright, University of North Carolina School of Medicine, Chapel Hill, North Carolina
摘要號：GS2-03
Does postmastectomy radiotherapy in intermediate-risk breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators.
在“中危”乳腺癌患者接受術後放療是否影響總生存期？BIG 2-04 MRC SUPREMO隨機試驗的10年結果：來自SUPREMO試驗研究者。
講者：Ian Kunkler, Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, Scotland
摘要號：GS2-05
Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
低風險導管原位癌（DCIS）患者接受積極監測或手術（±放療）的早期腫瘤學結果：比較手術與監測伴或不伴內分泌治療（COMET）研究（AFT-25）
講者：Eun-Sil Hwang, Duke University School of Medicine, Durham, North Carolina
摘要號：GS2-06
Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
DCIS患者接受積極監測或手術（±放療）後的患者報告結果：比較手術與監測伴或不伴內分泌治療（COMET）研究（AFT-25）
講者：Ann Partridge, Dana-Farber Cancer Institute, Boston, Massachusetts
摘要號：GS2-07
No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.
接受保乳術的早期浸潤性乳腺癌患者無腋窩清掃vs腋窩前哨淋巴結活檢：Intergroup-Sentinel-Mamma（INSEMA）試驗的最終主要結果。
講者：Toralf Reimer, Universitätsmedizin Rostock, Rostock, Germany
Rapid Fire Session
摘要號：RF2-01
Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial.
在Alliance A011202臨床試驗入組患者中，分析影響新輔助化療後殘留腋窩淋巴結陽性乳腺癌患者的淋巴結病變以及病理淋巴結分期上調的腋窩淋巴結清掃相關因素。
講者：Judy Boughey, Mayo Clinic, Rochester, Minnesot
摘要號：RF2-02
Axillary surgery after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies.
早期乳腺癌患者接受新輔助全身治療（NST）後的腋窩手術：5項新輔助治療研究中殘留微轉移的治療路徑和預後影響。
講者：Johannes Holtschmidt, VP Medicine & Research GBG Forschungs GmbH
摘要號：RF2-03
Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – results from the prospective AXSANA registry trial (NCT04373655).
新輔助化療後初診腋窩淋巴結陽性的乳腺癌患者行腋窩超聲的診斷效能：來自前瞻性AXSANA註冊試驗（NCT04373655）的結果。
講者：Steffi Hartmann, University of Rostock, Rostock, Germany
摘要號：RF3-06
Mepitel Film for the Reduction of Radiation Dermatitis in Post-mastectomy Radiation Therapy: Results from Alliance A221803: A Multicenter Phase III Randomized Clinical Trial
美菲膜（mepitel film）用於乳房切除術後放療期間以減少放射性皮炎：來自多中心、III期隨機臨床試驗Alliance A221803的結果。
講者：Kimberly Corbin, Mayo Clinic, Rochester, Minnesota
摘要號：RF3-07
ROSCO:Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil, Epirubicin & Cyclophosphamide vs Docetaxel & Cyclophosphamide chemotherapy.
ROSCO研究：可手術乳腺癌新輔助化療最佳選擇的療效反應：一項比較5-氟尿嘧啶、表柔比星和環磷醯胺 vs 多西他賽聯合環磷醯胺新輔助化療的隨機III期、分層生物標誌物試驗。
講者：Daniel Rea, University of Birmingham, Birmingham, United Kingdom
症狀監測與拓展分析
General Session
摘要號：GS1-06
PRO B–a superiority randomized controlled trial evaluating the effects of symptom monitoring in metastatic breast cancer patients.
PROB研究——一項評估轉移性乳腺癌患者症狀監測效果的優越性隨機對照試驗。
講者：Maria Margarete Karsten, Charité-Universitätsmedizin, Berlin
摘要號：GS2-09
Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database.
早期乳腺癌試驗協作組（EBCTCG）資料庫中206,904名女性超重、肥胖和預後情況
講者：Hongchao Pan, University of Oxford, Oxford, United Kingdom
摘要號：GS2-10
A long-term image-derived AI risk model for primary prevention of breast cancer.
一種用於乳腺癌一級預防的長期影象衍生AI風險模型。
講者：Mikael Eriksson, Karolinska Institutet, Solna, Sweden
摘要號：GS2-11
APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer.
APOBEC3突變誘導乳腺癌促耐藥性基因組改變。
講者：Avantika Gupta, Memorial Sloan Kettering Cancer Center, New York, New York
摘要號：GS3-08
In situ detection of individual classical MHC-I gene products in breast cancer identifies gene- and subtype-specific biased antigen presentation loss.
對乳腺癌中單個經典MHC-I基因產物的原位檢測，以識別基因和亞型特異性的偏倚抗原呈遞丟失。
講者：Paula Gonzalez-Ericsson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Rapid Fire Session
摘要號：RF1-01
Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (Alliance).
減重干預（WLI）對肥胖乳腺癌女性的代謝和炎症生物標誌物的影響：乳腺癌減重（BWEL）試驗（聯盟）的結果。
講者：Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, Massachusetts
摘要號：RF1-05
DNA methylation patterns are similar in benign tissue from ipsilateral and contralateral breast while different from matched breast cancer, and healthy controls.
同側與對側乳房的良性組織中DNA甲基化模式相似，但與配對的乳腺癌組織和健康對照組不同。
講者：Saya Dennis, Northwestern University Feinberg School of Medicine, Chicago, Illinois
摘要號：RF1-06
Association of polygenic-based breast cancer risk prediction with patient management.
基於多基因風險評估的乳腺癌預測與患者管理的相關性。
講者：Katie Johansen Taber, Myriad Genetics, San Francisco, California
摘要號：RF1-07
Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer.
度伐利尤單抗、曲妥珠單抗聯合帕妥珠單抗無化療方案（DTP試驗）治療HER2富集型早期乳腺癌的病理完全緩解（pCR）多因素分析。
講者：Bojana Stefanovska, UT Health Science Center, San Antonio, Texas
摘要號：RF2-05
Validation of the association between TILs, ER status and benefit of radiotherapy in node positive, breast cancer patients: a DBCG study.
淋巴結陽性乳腺癌患者的TILs、ER狀態與放療獲益的相關性驗證：DBCG研究。
講者：Demet Özcan, Aarhus University Hospital, Aarhus, Denmark
摘要號：RF2-06
A Nationwide Double-Blind Phase III RCT Comparing Olanzapine and Prochlorperazine for Refractory Chemotherapy-Induced Nausea in NCORP Community Practices.
在NCORP社群實踐中，探討奧氮平vs丙氯拉嗪治療時出現化療導致的難治性惡心的一項全國性、雙盲、III期、隨機對照試驗（RCT）。
講者：Luke Peppone, University of Rochester Medical Center, Rochester, New York
精彩資訊等你來
責任編輯：Sheep
*醫學界力求其發表內容專業、可靠，但不對內容的準確性做出承諾；請相關各方在採用或以此作為決策依據時另行核查。
